When an AI designs your antibody, the sequence is the cheap part. Proving it
does what the claim says is the rest of the work.

In this new article, Per Larsen, Ph.D., Partner and European Patent Attorney at aera explains the shift that is underway at the EPO. One word, “routine”, lets an examiner presume an antibody claim is enabled, and the same word is what makes the antibody look obvious. Generative AI pulls the two apart, and the weight moves onto what an applicant can show at the filing date.

How should you be drafting for that? Read the full piece here.